Business
Vericel Announces Preliminary 2025 Financial Results and Business Updates
Total Revenue Expected to be $276 Million MACI Revenue Expected to be $239.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% CAMBRIDGE,
About this update from Vericel Corporation
[{"type":"text","content":"Total Revenue Expected to be $276 Million MACI Revenue Expected to be $239.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% CAMBRIDGE, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced preliminary, unaudited financial results and other business updates for the fourth quarter and year ended December 31, 2025. Preliminary, Unaudited Full-Year 2025 Financial Results Total net revenue expected to be approximately $276 million, with MACI® net revenue of $239.5 million and Burn Care net revenue of $36.5 millionGross margin expected to be 74% and adjusted EBITDA margin expected to be 26%GAAP Net Income profitability expected for the second consecutive year$200 million in cash and investments, and no debt Business Highlights and Updates Highest number of MACI implants, implanting surgeons, surgeons taking biopsies and MACI biopsies in any quarter since launch in the fourth quarterMACI revenue growth of 20% or more for the third consecutive yearCompleted MACI sales force expansionMore than 900 MACI Arthro® trained surgeons as of year-end 2025Initiated MACI Ankle™ MASCOT clinical studyRemain on track to begin MACI commercial manufacturing in new facility in 2026 “The Company executed extremely well in 2025, delivering strong revenue and profitability growth,” said Nick Colangelo, President and CEO of Vericel. “We are entering 2026 with a great deal of momentum and expect another year of high revenue growth, increasing MACI utilization and further growth in profitability and cash generation as we continue to progress toward our mid-term financial targets.” Vericel is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference at 2:15 p.m. ET (11:15 a.m. PT) on Wednesday, January 14, 2026. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel Corporation Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel ma...